Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06482307

Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET

Status
Not Yet Recruiting
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
University Medical Center Groningen · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a single-centre, non-randomized, two-stage design, proof-of-concept study evaluating the radiolabelled PARP inhibitor \[18F\]-olaparib als potential tracer for imaging of tumour PARP expression by PET.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST[18F]-olaparib PET scanThe IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.

Timeline

Start date
2025-05-01
Primary completion
2026-02-01
Completion
2026-02-01
First posted
2024-07-01
Last updated
2025-04-18

Locations

1 site across 1 country: Netherlands

Source: ClinicalTrials.gov record NCT06482307. Inclusion in this directory is not an endorsement.